Skip to main content
SpringerLink
Log in

Osimertinib improves survival in NSCLC at high cost in Chile

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rojas R, et al. Cost Effectiveness of Osimertinib Versus Chemotherapy in Second Line Treatment of Non Small Cell Lung Cancer with Epidermal Growth Factor and 790M Mutation in Chilean Health System. 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN79, 18 May 2019.

  2. Balmaceda C, et al. Budget Impact Analysis of Osimertinib Versus Pemetrexed for the Second-Line Treatment of Advanced Lung Cancer with T790m Positive from Public Health Perspective in Chile. 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN83, 18 May 2019.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Osimertinib improves survival in NSCLC at high cost in Chile. PharmacoEcon Outcomes News 830, 25 (2019). https://doi.org/10.1007/s40274-019-5976-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5976-5

Search

Navigation